Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who have limited prior exposure to bortezomib. Thirty-three patients with relapsed multiple myeloma were enrolled. Ixazomib was given at 5.5 mg weekly for 3 of 4 weeks. Dexamet...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/
https://www.ncbi.nlm.nih.gov/pubmed/26275080
http://dx.doi.org/10.1038/bcj.2015.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558585/
https://www.ncbi.nlm.nih.gov/pubmed/26275080
http://dx.doi.org/10.1038/bcj.2015.60

Ejemplares similares